Tucatinib NEW
| Price | $30 | $45 | $72 |
| Package | 2mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-05-11 |
Product Details
| Product Name: Tucatinib | CAS No.: 937263-43-9 |
| Purity: 99.76% | Supply Ability: 10g |
| Release date: 2026/05/11 |
Product Introduction
Bioactivity
| Name | Tucatinib |
| Description | Tucatinib (ONT-380) is a potent and selective HER2 inhibitor (IC50: 8 nM). |
| In vitro | Irbinitinib selectively binds to and inhibits the phosphorylation of ErbB-2, which may prevent the activation of ErbB-2 signal transduction pathways, resulting in growth inhibition and death of ErbB-2-expressing tumor cells. |
| In vivo | In vivo,Tucatinib significantly inhibits tumor growth in multiple HER2-dependent tumor xenograft models[2]. It shows excellent activity in numerous mouse tumor models including breast (BT-474, MDA-MB-453), ovarian (SKOV-3) and gastric (N87) carcinoma models. In the BT-474 model,Tucatinib demonstrated significant dose-related tumor growth inhibition (TGI; 50% at 50 mg/kg/d and 96% at 100 mg/kg/d) with numerous partial regressions (>50% reduction from baseline size)[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 45 mg/mL (93.65 mM), Sonication is recommended. Ethanol : 15 mg/mL (31.22 mM), Sonication is recommended. |
| Keywords | Tucatinib | p95 HER2 | ONT380 | ONT 380 | Inhibitor | inhibit | HER2/ErbB2 | HER1 | ErbB-1 | Epidermal growth factor receptor | EGFR | ARRY380 | ARRY 380 |
| Inhibitors Related | (S)-Afatinib | Osimertinib | Lidocaine Hydrochloride hydrate | Lapatinib | Erlotinib hydrochloride | Erlotinib | Neratinib | Afatinib | Chalcone | Brigatinib | Genistein | Gefitinib |
| Related Compound Libraries | Highly Selective Inhibitor Library | Membrane Protein-targeted Compound Library | Kinase Inhibitor Library | EMA Approved Drug Library | Tyrosine Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Inhibitor Library | FDA-Approved Drug Library | FDA-Approved Kinase Inhibitor Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
VIP3Y
|
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
|
2026-07-07 | ||
|
VIP3Y
|
Hangzhou Hyper Chemicals Limited
|
2026-05-29 | ||
|
VIP7Y
|
Zison Pharmaceutical (Shandong) Co., Ltd.
|
2025-12-15 | ||
|
HangZhou RunYan Pharma Technology Co.,LTD.
|
2025-08-21 | |||
|
VIP4Y
|
Zhengzhou Anbu Chem Co.,Ltd
|
2025-03-21 | ||
|
Nanjing Fred Technology Co., Ltd
|
2024-11-26 | |||
| $15.00 |
Zhuozhou Wenxi import and Export Co., Ltd
|
2021-07-13 | ||
| $1.00 |
VIP7Y
|
Career Henan Chemical Co
|
2020-01-02 | |
|
VIP3Y
|
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
|
2026-07-07 | ||
| $15.00 |
Zhuozhou Wenxi import and Export Co., Ltd
|
2021-07-10 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY